|
M.E. Statsenko, S.V. Turkina, I.A. Tyschenko, M.A. Kosivtsova, S.A. Kostromeev
Effect of Tadalafil SZ on endothelial function in patients with erectile dysfunction
|
№1 / 2021
|
|
A.A. Kamalov, A.N. Nizov
Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction
|
№4 / 2019
|
|
I.L. Nikitina, G.G. Gaysina, Sh.N. Galimov, K.V. Bulygin, E.F. Galimova, V.N. Pavlov
Safety of tadalafil in patients with cardiovascular comorbidities
|
№1 / 2019
|
|
E.A. Efremov, E.V. Kasatonova, Ya.I. Mel'nik, A.A. Nikushina
The role of tadalafil in the management of sexual dysfunctions
|
№2 / 2018
|
|
A.A. Volkov, M.I. Petrichko, N.V. Budnik
Correction of erectile dysfunction in patients with BPH using daily administration of tadalafil 5 mg against the background of combined drug therapy
|
№5 / 2013
|
|
A.A. Volkov, M.I. Petrichko, N.V. Budnik, A.R. Dukhin.
Tadalafil in patients with benign prostatic hyperplasia during conservative combined therapy
|
№2 / 2013
|
Русский
